8-K

from 8-K 5 pages 8-K

11/13/24

EX-99.1

from 8-K 5 pages X4 Pharmaceuticals Announces Positive Results From Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia

11/13/24

EX-99.2

from 8-K 29 pages Press releases and additional exhibits

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio001.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio002.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio003.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio004.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio005.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio006.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio007.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio008.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio009.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio010.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio011.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio012.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio013.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio014.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio015.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio016.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio017.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio018.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio019.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio020.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio021.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio022.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio023.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio024.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio025.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio026.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio027.jpg

11/13/24

GRAPHIC

from 8-K a992corporatepresentatio028.jpg

11/13/24

GRAPHIC

from 8-K x4logo.jpg

11/13/24